The Skin Cancer after Organ Transplant (SCOT) study was designed to investigate the link between genus beta human papillomavirus (HPV) and squamous cell skin cancer (SCSC). We focused on a population receiving immunosuppressive therapy for extended periods, transplant patients, as they are at extremely high risk for developing SCSC. Two complementary projects were conducted in the Seattle area: (i) a retrospective cohort with interview data from 2004 recipients of renal or cardiac transplants between 1995 and 2010 and (ii) a prospective cohort with interview data from 328 people on the transplant waiting lists between 2009 and 2011. Within the retrospective cohort, we developed a nested case-control study (172 cases and 337 control subjects) to assess risk of SCSC associated with markers of HPV in SCSC tumour tissue and eyebrow hair bulb DNA (HPV genotypes) and blood (HPV antibodies). In the prospective cohort, 135 participants had a 1-year post-transplant visit and 71 completed a 2-year post-transplant visit. In both arms of the cohort, we collected samples to assess markers of HPV infection such as acquisition of new types, proportion positive for each type, persistence of types at consecutive visits and number of HPV types detected. In the prospective cohort, we will also examine these HPV markers in relation to levels of cell-mediated immunity. The goal of the SCOT study is to use the data we collected to gain a more complete understanding of the role of immune suppression in HPV kinetics and of genus beta HPV types in SCSC. For more information, please contact the principal investigator through the study website: http://www.fhcrc.org/science/phs/cerc/The_SCOT_Study.html.
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Many malignancies that occur in high excess in OTR are attributable to viruses that thrive in the setting of immune suppression, such as Epstein Barr virus-associated non-Hodgkin lymphomas, hepatitis viruses and liver cancers and human papillomavirus (HPV)-related anogenital cancers. SCSC may also be related to a virus. Initial evidence pointed to HPV as a candidate virus in SCSC, as HPV was found in patients with a rare autosomal recessive disease, epidermodysplasia verruciformis.
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Epidermodysplasia verruciformis patients present with immune dysfunction and disseminated skin lesions that resemble warts. About one-third of these patients develop SCSC on sun-exposed areas of their skin, and genus beta HPV types have been detected in 490% of SCSC tumours in these patients. 12 Recent studies suggest various mechanisms by which beta HPV types might be involved in SCSC carcinogenesis. These viruses have been shown to block apoptosis by interfering with the Bak protein in sun-damaged epithelial cells, allowing damaged cells to accumulate. 13, 14 In another study, beta HPV5 and beta HPV8 E6 proteins were found to interact with p300, promoting its instability. 15 Together, these studies add to the evidence in support of a role for HPV in SCSC.
The Skin Cancer after Organ Transplant (SCOT) study was designed to investigate the putative link between beta HPV and SCSC in the context of immune suppression, and with the understanding that UV exposure is likely the key initiator of SCSC. Our over-arching goal was to provide evidence that would establish a role for beta HPV in SCSC development. If a definitive link between genus beta HPV and SCSC can be established, it might lead to new approaches to prevention and treatment of SCSC in both transplant patients and members of the general population.
To achieve these goals, we conducted two related studies in the Seattle area: (i) a large retrospective cohort study with a nested case-control study conducted among kidney and heart transplant recipients who received their transplants between 1995 and 2010 and (ii) a prospective longitudinal cohort study among OTR that enrolled adults on the kidney and heart transplant waiting lists to examine viral kinetics in a longitudinal study, with data collected pretransplant and 1 and 2 years post-transplant. The study goals were to assess markers of beta HPV from SCSC tumour tissue, eyebrow hair samples or serum samples for evidence of genus beta HPVs. Further, interview information on sun sensitivity and exposure history, medication use, genetic predisposition and other factors will be examined as cofactors of an association between beta HPV and SCSC.
Who is in the cohort?
The SCOT study cohort enrolled renal and cardiac transplant recipients in the Seattle area: a retrospective cohort (n ¼ 2004) transplanted between 1995 and 2010 and a prospective cohort (n ¼ 328) transplanted between 2009 and 2011. Within the retrospective cohort, we developed a nested case-control study (172 cases and 337 control subjects) to assess risk of SCSC associated with markers of HPV in SCSC tumour tissue and hair follicles and blood. All study protocols and documents were approved by institutional review boards, and no monetary inducements were provided for joining the study.
Retrospective cohort
Using data from the transplant centres, we mailed a letter of approach, an informed consent document and a 4-page questionnaire to the 2731 transplant recipients who had been transplanted between 1995 and 2010 and were not known to have died as of the start of study recruitment (April 2008). To find potential participants for whom the address from the transplant centre was no longer accurate, we searched state and federal data sources, such as Washington state drivers' licence and electoral rolls and internet sources. We enrolled 2004 (73.4%) OTR in the SCOT cohort study.
Inclusion criteria for the retrospective cohort were having a first kidney, kidney and pancreas or heart transplant at one of the three transplant centres in Seattle between 1995 and 2010; having an intact graft for at least 3 months; being 518 years of age as of the date of transplant; having no history of a SCSC diagnosis before transplant; able to communicate in English and being a resident of Washington, Idaho, Alaska, Montana or Wyoming at the time of transplant. Transplant recipients may have received more than one transplant during the study period as long as their graft functioned for at least 3 months.
Based on publicly available data from the US Department of Health and Human Services, Organ Procurement and Transplantation Network (OPTN), (http://optn.transplant.hrsa.gov/), there were 4112 adult heart, kidney or kidney and pancreas transplant recipients at the three transplant centres during the study period. These data suggest that we were able to identify $81% (n ¼ 3317) of potentially eligible cohort members. In Table 1 , we compare the SCOT study participants' transplant characteristics with data available from the OPTN website for our transplant centres to gauge the representativeness of our study to the local OTR population, and the groups are generally similar.
The main reasons for non-response were death before contact (18%), death after attempted recruitment (2%), loss to follow-up/untraceable (11%) and refusal to participate (9%) ( Table 2) . Of the 2004 enrolled cohort members, 1180 participants (43%) returned the 4-page mailed questionnaire by mail and 824 participants (30%) filled out the same questionnaire over the phone. In Table 2 , loss to follow-up over time is described for those who died before the study started, who were not traceable or who refused contact. Although no information is available on these OTR, Table 1 suggests that the patients who were followed are representative of all patients in the study catchment who were reported to OPTN.
Nested case-control study of SCSC The nested case-control study design allows us to accurately estimate relative risk for the whole cohort, but is efficient because it focuses on all cases and a matched subset of the cohort as control subjects. Cases were identified by reviewing pathology reports from potential case subjects who reported a skin biopsy after transplant. We confirmed 195 SCSC cases nested within the cohort. Among those 195 cases, 172 (88%) agreed to participate in the nested case-control study. We selected control subjects from among the retrospective cohort participants.
Control subjects were matched to cases on the following factors: time since transplant (exact number of months), age at transplant (AE5 years), year of transplant (AE2 years), organ transplanted, hospital, donor type (living versus deceased), gender and race (White versus non-White). When necessary, matching factors were prioritized, and highest priority was given to time since transplant, organ transplanted and sex. We enrolled 337 participants as control subjects, which was 81% of the total number of control subjects approached.
Prospective cohort
The prospective cohort was identified from the local transplant waiting lists starting in 2009. Inclusion criteria were as follows: being a resident of one of six counties in the Seattle metropolitan area (King, Pierce, Snohomish, Skagit, Whatcom and Thurston), being on the heart or kidney transplant list in 2009 through 2011 and being 525 years of age. We contacted 636 eligible participants by mail and asked them to fill out a 4-page questionnaire. We recruited 328 participants who completed a short in-person interview and donated blood and eyebrow samples. Among the 328 prospective SCOT study cohort members, 201 (61%) received a transplant (as of March 2012). Among them, 135 (67%) had a 1-year post-transplant study visit and 71 (53%) had a 2-year post-transplant visit; thus, 71 OTR had three longitudinal study visits. In addition, study participants who did not receive a transplant were asked to return annual 4-page questionnaires to ascertain whether these patients remained eligible for the study. How often have they been followed up? Table 3 describes the timing of sample and data collection for the retrospective cohort, nested case-control study and prospective study that together make up the SCOT study. The study began active data collection in April 2008 and completed data collection in March 2012. Of the 2004 members enrolled in the retrospective cohort who completed the initial questionnaire, 1708 patients completed the first annual follow-up questionnaire (85%) and 1407 completed a second follow-up questionnaire (70%). For the nested case-control study, participants were followed annually during the data collection period with short mailed questionnaires after they completed the long, in-person interview. For the prospective cohort, 328 participants were enrolled from the waiting lists between 2009 and 2011. A longer in-person interview was conducted at 1 year post-transplant (n ¼ 135 completed) and a short in-person interview was completed at 2-year post-transplant time point (n ¼ 71 completed). Median follow-up time for participants in the retrospective cohort was 84.4 months (SD 49.9) from transplant to last contact. In the nested case-control study, median time from transplant to reference date (diagnosis or similar date for control subjects) was 63.8 months for control subjects (SD 38.1) and 64.7 months for cases (SD 38.3). Median follow-up time for the prospective cohort was 15.5 months (SD 6.4) from transplant to last contact.
What has been measured? Questionnaires
The retrospective and prospective cohort members received annual 4-page follow-up questionnaires during the study (April 2008-March 2012). The initial questionnaire asked about any full body skin examinations by a dermatologist, skin conditions and skin biopsies as well as information on graft status, skin type and demographics. Annual short questionnaires repeated these questions and added additional questions on UV exposure, medication history and other health conditions (Table 3) .
A more detailed, in-person interview was given to all participants in the nested case-control study and was also used as the first follow-up questionnaire (at the 1-year post-transplant visit) in the prospective cohort. The longer questionnaire focused on residence history; history of UV exposure; skin type; use of sunscreen and tanning devices; general medication history, including transplant medications; non-steroidal anti-inflammatory use and use of steroids; family history of cancer; comorbidities including any personal history of cancer, history of diabetes, time on dialysis, indication for transplant, sexual history, active and passive smoking history, reproductive history, body size, race and grandparents' countries of origin.
Laboratory assays
Our molecular biology laboratory developed typespecific antibody and DNA genotyping assays for genus beta HPV types. The beta HPV serological assays developed to the L1 proteins of the various beta HPV types allow us to examine risk of SCSC associated with specific beta HPV types in the entire cohort. All OTR have a blood sample stored at the time of transplant, and we retrieved serum from study participants who consented. Those participating in the nested case-control study had a second blood sample drawn (serum, plasma, buffy coat) at the time of the in-person interview. We also are able to examine whether antibodies to several of the human polyomaviruses (PyV, e.g. Merkel cell PyV, KIPyV, JCPyV, BKV, WUPyV, HPyV6, HPyV7) are associated with SCSC. 16 In the nested case-control study, we plan to examine beta HPV genotypes in eyebrow hairs collected at the time of the in-person interview, as hair follicles are potentially a reservoir for genus beta HPV, 17 and the forehead is a sun exposed area where SCSC commonly occurs. We also plan to assay HPV genotypes in stored SCSC tumour tissue that we have retrieved for cases (n ¼ 125/172) and compare those with beta HPV types found in eyebrow hairs.
As a measure of immune suppression, we collected whole blood for the ImmuKnow assay (Cylex), which The number eligible for the study that had not died as of the start of data collection was 2731, which was used as the denominator for the response proportion of 73.2%; we did not have information on transplant year for 26 refusers. b Of the 195 confirmed cases, 172 (88.2%) agreed to participate in the case-control study. is a global immune function test that measures lymphocyte stimulation after incubation with a mitogen (PHA) by assessing generation of ATP. These assays are run using samples collected from the prospective cohort participants at the pre-transplant study visit and at 1-and 2-year post-transplant study visit.
Light meter
We use a CR-400 Konica Minolta light meter to assess sun reflectance on the back of the hand and on the less sun-exposed ventral forearm for all patients in the nested case-control and longitudinal studies to characterize skin colour, including indices of erythema and melanin content of the skin through light reflectance. The light meter will also provide an objective measure of skin colour changes over the time course of the prospective cohort.
What has it found? Key findings and publications
Results from the nested case-control study are summarized in Table 4 . Men were more predominant in the case group (76.7%) than the cohort overall (59.1%), though control subjects were matched to cases on sex, making the groups comparable. The groups were also very similar with respect to time since transplant. Using conditional logistic regression analysis, we found that measures of sensitivity to UV light resulted in excess risk of SCSC with blue (but not green) eye colour, light hair, sunburn (including history of blistering burns) and resistance to tanning were significantly related to SCSC. In the retrospective cohort, only 54% of patients reported having had a full-body examination by a dermatologist, despite recommendations by most transplant physicians that OTR have yearly dermatological screenings. The proportion of OTR with SCSC who reported screening was higher (87%) than that in the cohort overall, as was the proportion of matched control subjects who reported dermatological screening (62%). In the nested case-control study, high rates of insurance coverage were reported, as expected, for 490% of participants. Nearly all participants reported that their insurance plan did cover dermatology services (98.2%).
What are the main strengths and weaknesses?
A major strength of the SCOT study is that blood specimens were available from the immediate pre-transplant period for all participants in the study. This will allow us to evaluate associations between pre-diagnostic serum markers of viral infection and subsequent risk of SCSC in the nested case-control study. In the prospective study, which collected blood longitudinally at three time points, we will explore the changes in serological response to HPV (and HPV genotype from eyebrow hairs), in relation to level of immune suppression as measured. These stored samples may also be useful for future testing.
In the nested case-control study, we collected additional sera at the time of the in-person interview and will be able to assess the impact of changes in beta HPV serology between the pre-transplant and interview blood draws. Furthermore, the casecontrol study has been matched carefully on a number of variables such as age at transplant, time since transplant and year of transplant, to limit confounding by these factors. We have also obtained medical records releases from study participants, which will allow us to explore ancillary hypotheses. Odds ratios and confidence intervals generated using conditional logistic regression accounting for matched case-control pairs and adjusted for linear age at reference to account for possible residual confounding by grouped age-matching. Matching factors for the case-control study: time since transplant, age at transplant, year of transplant, organ transplanted, hospital, donor type, sex and race.
A limitation of the study is that the nested casecontrol study has retrospective ascertainment (for the transplant years 1995-2008); thus, although blood samples were drawn pre-transplant and at the time of the interview, we will not have blood samples collected during the post-transplant period before SCSC treatment. This may influence measurement of the HPV markers, as treatment could affect the levels of circulating antibody.
Other measures such as sun exposure history and immune suppression medication, may be differential for cases compared with control subjects owing to potential risk of SCSC. Fortunately, the blood draw for all pre-transplant will be available to examine risk of primary SCSC associated with pre-diagnostic serum markers.
The SCOT study appears to be representative of the renal and cardiac transplant recipients in the US Northwest, and may therefore be generalizable to other OTR populations in the USA. We were able to ascertain the number of transplant surgeries conducted in our catchment area using publicly available data from the US OPTN (http://optn.transplant.hrsa. gov/). Indeed, a motivation for this study is that, as there is an increasing epidemic of SCSC in the general population of the USA, 18 this study may be important to understanding mechanisms of SCSC development that extend beyond this high risk and most adversely affected population.
Can I get hold of the data? Where can I find out more?
We welcome development of new collaborations to address additional compelling hypotheses in the SCOT study cohort, dependent on ethics board (institutional review board) approval. We request a short research proposal that should include information on the hypothesis, timeline, methods and budget. Approval of the proposal depends on the topic and quality of the proposal. We hope to collaborate with other researchers with similar data to expand our ability to address key scientific questions. One area of particular interest to us, genetic variation in key pathways that may affect development of SCSC, would benefit greatly from multicentre efforts to increase sample size. For more information, please contact us through the study website: http://www.fhcrc .org/science/phs/cerc/The_SCOT_Study.html, or contact the SCOT study principal investigator, Dr Margaret Madeleine, at 1-206-667-4630 or scot@fhcrc.org.
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KEY MESSAGES
The proportion of solid organ transplants in the Seattle area with SCSC was 4.5% among kidney transplants and 8.5% among heart transplants at 5 years and 7.8 and 15.5% at 10 years, respectively.
The incidence of SCSC among transplant recipients in this cohort is lower than prior reports and may reflect changes in the medications used to supress graft rejection.
Only 54% of transplant recipients in this cohort (545/2004) reported seeing a dermatologist, despite advice to do so.
